The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Open accessAbstract
Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Self-citationPeiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Self-citationRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13615-x · Cited by 1,158
Donnelly, C. A., Ghani, A. C., Leung, G. M., Hedley, A. J., Fraser, C., Riley, S., Abu-Raddad, L. J., Ho, L.-M., Thach, T.-Q., Chau, P., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13410-1 · Cited by 940 · cited 2×
“Since all age groups are affected and a high fatality is noted in the elderly and those with co-morbidities (Donnelly et al., 2003) , there is an urgent need to find a cure.”
Self-citationTreatment of SARS with human interferons
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13973-6 · Cited by 467
Flavonoid Baicalin Inhibits HIV-1 Infection at the Level of Viral Entry
Li, B. Q., Fu, T., Dongyan, Y., Mikovits, J. A., Ruscetti, F. W., & Wang, J. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3485 · Cited by 258
Early diagnosis of SARS Coronavirus infection by real time RT-PCR
Poon, L. L. M., Chan, K. H., Wong, O. K., Yam, W. C., Yuen, K. Y., Guan, Y., Lo, Y. M. D., & Peiris, J. S. M. (2003) · Journal of Clinical Virology · doi:10.1016/j.jcv.2003.08.004 · Cited by 198
Self-citationDouglas, R. M., Moore, B. W., Miles, H. B., Davies, L. M., Graham, N. M. H., Ryan, P., Worswick, D. A., & Albrecht, J. K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601093140201 · Cited by 167
Baicalin, an inhibitor of HIV-1 production in vitro
Kitamura, K., Honda, M., Yoshizaki, H., Yamamoto, S., Nakane, H., Fukushima, M., Ono, K., & Tokunaga, T. (1998) · Antiviral Research · doi:10.1016/s0166-3542(97)00069-7 · Cited by 157
Immune-Mediated Complications during Interferon Therapy in Hematological Patients
Raanani, P., & Ben‐Bassat, I. (2002) · Acta Haematologica · doi:10.1159/000057631 · Cited by 128
Foster, G. R., RODRIGUES, O., Ghouze, F., Schulte‐Frohlinde, E., Testa, D., Liao, M. J., Stark, G. R., Leadbeater, L., & Thomas, H. C. (1996) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1996.16.1027 · Cited by 117
Artemisinin drugs: novel antimalarial agents
Price, R. N. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1815 · Cited by 115
Intranasal Interferon- 2, Treatment of Experimental Rhinoviral Colds
Hayden, F. G., & Gwaltney, J. M. (1984) · Journal of Infectious Diseases · doi:10.1093/infdis/150.2.174 · Cited by 109 · cited 2×
“This was unexpected because intranasal leucocyte or recombinant interferon-alpha protect against experimental human infection by rhinovirus, coronavirus, and respiratory syncytial virus (Hayden and Gwaltney, 1984; Higgins et al., 1983; Higgins et al., 1990) .”
BackgroundHiggins, P. G., Phillpotts, R. J., Scott, G. M., Wallace, J., Bernhardt, L. L., & Tyrrell, D. A. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.24.5.713 · Cited by 90
The efficacy of intranasal interferonα-2a in respiratory syncytial virus infection in volunteers
Higgins, P. G., Barrow, G. I., Tyrrell, D. A. J., Isaacs, D., & Gauci, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90061-b · Cited by 50
Lü, H., Jiang, Y., & Chen, F. (2003) · Journal of Chromatography A · doi:10.1016/j.chroma.2003.08.012 · Cited by 42
Self-citation
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,603
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Self-citation
Metadata
- Authors
- Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W.
- Venue
- Journal of Clinical Virology
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 31
- Issue
- 1
- Pages
- 69-75
- ISSN
- 1386-6532 (ISSN-L)
- OpenAlex
- W2166189758
- Cited by
- 534
- References
- 17
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.